Main laboratory and clinical characteristics of the 19 patients with MC and severe CLD
| Pt no. . | Sex . | Age, y . | CLD duration, mo . | MCS duration, mo/cryoglobulin type . | HCV genotype . | Histology [Metavir score] (Child-Pugh Class) . | Arthralgias . | Cutaneous manifestations . | Nephritis . | Neuropathic symptoms . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 44 | 146 | 50/II | 4c/4d | CH [A3 F3] | No | No | No | Yes |
| 2 | F | 74 | 173 | 64/II | 2a/2c | CH [A1 F3] | Yes | P(+) | No | Yes |
| 3 | F | 37 | 114 | 123/III | NA | C (A6) | Yes | P(++); 1 leg ulcer | Yes | Yes |
| 4 | F | 66 | 179 | 71/II | 1b | C (C11) | Yes | P(++) | Yes | Yes |
| 5 | F | 71 | 106 | 106/II | 1b | C (B7) | Yes | P(+) | No | Yes |
| 6 | M | 68 | 251 | 47/II | 1b | CH [A2 F3] | No | P(+++) | Yes | Yes |
| 7 | F | 54 | 188 | 44/II | 2a/2c | C (B7) | Yes | P(++) | No | Yes |
| 8 | M | 60 | 149 | 65/II | 1b | C (B8) | Yes | P(+ +) | Yes | Yes |
| 9 | F | 69 | 75 | 75/II | 2a/2c | C (A5) | Yes | P(+) | No | Yes |
| 10 | F | 75 | 181 | 145/II | 1b | C (A5) | Yes | P(+) | No | Yes |
| 11 | M | 61 | 134 | 134/II | 1b | C (A6) | No | P(++) | No | Yes |
| 12 | M | 77 | 134 | 134/II | 1b | C (A5) | Yes | P(++) | No | Yes |
| 13 | F | 58 | 170 | 86/II | 1b | C (A6) | Yes | No | No | Yes |
| 14 | M | 66 | 173 | 137/II | 1b | C (B9) | No | P(++) | No | No |
| 15 | M | 46 | 132 | 24/II | 1b | C (B9) | Yes | P(+++); 3 leg ulcers | Yes | Yes |
| 16 | F | 68 | 207 | 111/III | 2a/2c | CH [A2 F3] | Yes | P(+++) | No | Yes |
| 17 | F | 66 | 172 | 172/II | 2a/2c | C (A5) | Yes | P(++) | No | Yes |
| 18 | F | 71 | 444 | 180/II | 2a/2c | C (A5) | Yes | P(++); 2 leg ulcers | No | Yes |
| 19 | F | 66 | 366 | 30/II | 1b | C (A6) | Yes | P(+) | No | Yes |
| Pt no. . | Sex . | Age, y . | CLD duration, mo . | MCS duration, mo/cryoglobulin type . | HCV genotype . | Histology [Metavir score] (Child-Pugh Class) . | Arthralgias . | Cutaneous manifestations . | Nephritis . | Neuropathic symptoms . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 44 | 146 | 50/II | 4c/4d | CH [A3 F3] | No | No | No | Yes |
| 2 | F | 74 | 173 | 64/II | 2a/2c | CH [A1 F3] | Yes | P(+) | No | Yes |
| 3 | F | 37 | 114 | 123/III | NA | C (A6) | Yes | P(++); 1 leg ulcer | Yes | Yes |
| 4 | F | 66 | 179 | 71/II | 1b | C (C11) | Yes | P(++) | Yes | Yes |
| 5 | F | 71 | 106 | 106/II | 1b | C (B7) | Yes | P(+) | No | Yes |
| 6 | M | 68 | 251 | 47/II | 1b | CH [A2 F3] | No | P(+++) | Yes | Yes |
| 7 | F | 54 | 188 | 44/II | 2a/2c | C (B7) | Yes | P(++) | No | Yes |
| 8 | M | 60 | 149 | 65/II | 1b | C (B8) | Yes | P(+ +) | Yes | Yes |
| 9 | F | 69 | 75 | 75/II | 2a/2c | C (A5) | Yes | P(+) | No | Yes |
| 10 | F | 75 | 181 | 145/II | 1b | C (A5) | Yes | P(+) | No | Yes |
| 11 | M | 61 | 134 | 134/II | 1b | C (A6) | No | P(++) | No | Yes |
| 12 | M | 77 | 134 | 134/II | 1b | C (A5) | Yes | P(++) | No | Yes |
| 13 | F | 58 | 170 | 86/II | 1b | C (A6) | Yes | No | No | Yes |
| 14 | M | 66 | 173 | 137/II | 1b | C (B9) | No | P(++) | No | No |
| 15 | M | 46 | 132 | 24/II | 1b | C (B9) | Yes | P(+++); 3 leg ulcers | Yes | Yes |
| 16 | F | 68 | 207 | 111/III | 2a/2c | CH [A2 F3] | Yes | P(+++) | No | Yes |
| 17 | F | 66 | 172 | 172/II | 2a/2c | C (A5) | Yes | P(++) | No | Yes |
| 18 | F | 71 | 444 | 180/II | 2a/2c | C (A5) | Yes | P(++); 2 leg ulcers | No | Yes |
| 19 | F | 66 | 366 | 30/II | 1b | C (A6) | Yes | P(+) | No | Yes |
Pt indicates patient; CLD, chronic liver disease; MCS, mixed cryoglobulinemia syndrome; CH, chronic hepatitis; C, cirrhosis; P, purpura; +, limited or fluctuating involvement of the lower limbs; ++, diffuse and persistent involvement of the lower limbs; and +++, diffuse and persistent involvement of the trunk and lower limbs.